Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Bonanno

Showing results (81-90 of 126) with videos related to

Pageof 13
Sort By:
Journal of Experimental & Clinical Cancer Research : CR|June 19, 2025
Baseline levels and dynamic changes of cfDNA, tumor fraction and mutations to anticipate the clinical course of small cell lung cancer (SCLC) patients treated with first-line atezolizumab and chemotherapy: an hypothesis generating study (CATS/ML43257)Giulia Pasello, Giulia Pigato, Daniela Scattolin, et al.
BMC Cancer|May 16, 2016
Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancerLaura Bonanno, Carlota Costa, Margarita Majem, et al.
Oncotarget|April 22, 2017
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutationsStefano Frega, Martina Lorenzi, Matteo Fassan, et al.
Clinical Lung Cancer|October 15, 2019
ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS)Rita Chiari, Biagio Ricciuti, Lorenza Landi, et al.
Cancers|November 26, 2022
The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic TreatmentsAlessandra Ferro, Matteo Sepulcri, Marco Schiavon, et al.
British Journal of Cancer|May 8, 2020
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancerElisabetta Zulato, Ilaria Attili, Alberto Pavan, et al.
Current Oncology (Toronto, Ont.)|February 25, 2025
Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel MeetingFilippo de Marinis, Andrea Ardizzoni, Ilaria Attili, et al.
The Journal of Pathology|May 21, 2011
Notch3 signalling promotes tumour growth in colorectal cancerValentina Serafin, Luca Persano, Lidia Moserle, et al.
Frontiers in Oncology|April 21, 2025
Liver kinase B1 expression is associated with improved prognosis and tumor immune microenvironment features in small cell lung cancerAlessandro Dal Maso, Federica Ferrarini, Giovanni Esposito, et al.
Translational Lung Cancer Research|February 11, 2021
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcomeAlberto Pavan, Andrea Boscolo Bragadin, Lorenzo Calvetti, et al.
Pageof 13

Showing results (81-90 of 126) with videos related to

Sort By:
Pageof 13
Journal of Experimental & Clinical Cancer Research : CR|June 19, 2025
Baseline levels and dynamic changes of cfDNA, tumor fraction and mutations to anticipate the clinical course of small cell lung cancer (SCLC) patients treated with first-line atezolizumab and chemotherapy: an hypothesis generating study (CATS/ML43257)Giulia Pasello, Giulia Pigato, Daniela Scattolin, et al.
BMC Cancer|May 16, 2016
Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancerLaura Bonanno, Carlota Costa, Margarita Majem, et al.
Oncotarget|April 22, 2017
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutationsStefano Frega, Martina Lorenzi, Matteo Fassan, et al.
Clinical Lung Cancer|October 15, 2019
ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS)Rita Chiari, Biagio Ricciuti, Lorenza Landi, et al.
Cancers|November 26, 2022
The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic TreatmentsAlessandra Ferro, Matteo Sepulcri, Marco Schiavon, et al.
British Journal of Cancer|May 8, 2020
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancerElisabetta Zulato, Ilaria Attili, Alberto Pavan, et al.
Current Oncology (Toronto, Ont.)|February 25, 2025
Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel MeetingFilippo de Marinis, Andrea Ardizzoni, Ilaria Attili, et al.
The Journal of Pathology|May 21, 2011
Notch3 signalling promotes tumour growth in colorectal cancerValentina Serafin, Luca Persano, Lidia Moserle, et al.
Frontiers in Oncology|April 21, 2025
Liver kinase B1 expression is associated with improved prognosis and tumor immune microenvironment features in small cell lung cancerAlessandro Dal Maso, Federica Ferrarini, Giovanni Esposito, et al.
Translational Lung Cancer Research|February 11, 2021
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcomeAlberto Pavan, Andrea Boscolo Bragadin, Lorenzo Calvetti, et al.
Pageof 13